FINWIRES · TerminalLIVE
FINWIRES

$NKTR

4 stories mentioning NKTR

Every FINWIRES story that references NKTR, newest first.

Sectors

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Tvardi Therapeutics (TVRD) shares fell 4.1% after Barclays downgraded the company's stock to underweight from equalweight and adjusted the price target to $3 from $4.Eli Lilly (LLY) has agreed to buy clinical-stage biotechnology firm Kelonia Therapeutics for up to $7 billion, as the drugmaker looks to bolster its cancer treatment portfolio. Lilly shares were easing 0.6%.Compass Pathways (CMPS), GH Research (GHRS), and other psychedelic companies' shares were up on Monday, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness. Compass shares surged 42%, and GH Research jumped 17%.Nektar Therapeutics (NKTR) shares climbed 18% after it said Monday that data from a 16-week extension period of its phase 2b study of rezpegaldesleukin showed a "deepening of response" in people with severe-to-very-severe alopecia areata.

$CMPS$GHRS$LLY$NKTR$TVRD
Sectors

Sector Update: Health Care Stocks Softer Monday Afternoon

Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.5%.The iShares Biotechnology ETF (IBB) was down 0.2%.In corporate news, Eli Lilly (LLY) has agreed to buy clinical-stage biotechnology firm Kelonia Therapeutics for up to $7 billion, as the drugmaker looks to bolster its cancer treatment portfolio. Lilly shares were easing 0.1%.Compass Pathways (CMPS), GH Research (GHRS), and other psychedelic companies' shares were up on Monday, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness. Compass shares surged 47%, and GH Research jumped 15%.Nektar Therapeutics (NKTR) shares climbed 22% after it said Monday that data from a 16-week extension period of its phase 2b study of rezpegaldesleukin showed a "deepening of response" in people with severe-to-very-severe alopecia areata.

$CMPS$GHRS$LLY$NKTR
Wire

Top Midday Gainers

Nektar Therapeutics (NKTR) said Monday that data from a 16-week extension period of its phase 2b study of rezpegaldesleukin showed a "deepening of response" in patients with severe-to-very-severe alopecia areata.Wedbush Securities lifted its price target for Nektar Therapeutics' shares to $95 from $70 while maintaining the stock's neutral rating.Shares of Nektar jumped 22%, with intraday trading volume of nearly 3.4 million, up from a daily average of about 1.1 million.Compass Pathways (CMPS), GH Research (GHRS), and other psychedelic companies' shares were up on Monday, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness.Shares of Compass Pathways surged 49% as intraday trading volume soared to over 29 million from a daily average of about 3.05 million.GH Research shares advanced 14% as intraday trading volume jumped to over 953,700 from a daily average of roughly 192,000.Price: $103.50, Change: $+18.64, Percent Change: +21.97%

$CMPS$GHRS$NKTR
Wire

Wedbush Lifts Price Target on Nektar Therapeutics to $95 From $70, Maintains Neutral Rating

Nektar Therapeutics (NKTR) has an average rating of buy and mean price target of $130.62, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $104.82, Change: $+19.96, Percent Change: +23.52%

$NKTR